Видео ютуба по тегу Biocon Expansion Plans

How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
Biocon CEO On Raising Rs 4,500 Through QIP & Expansion Plans
Biocon CEO On Raising Rs 4,500 Through QIP & Expansion Plans
Dr.Shaw on Biocon's expansion plans - Interview with CNBC.mpg
Dr.Shaw on Biocon's expansion plans - Interview with CNBC.mpg
Biocon Biologics: Strong Earnings In Q2, What's Expansion & Capex Utilisation Plans?; Shreehas Tambe
Biocon Biologics: Strong Earnings In Q2, What's Expansion & Capex Utilisation Plans?; Shreehas Tambe
Бизнес-коридор Бангалора: правительство одобрило крупный проект по сокращению пробок в Бангалоре ...
Бизнес-коридор Бангалора: правительство одобрило крупный проект по сокращению пробок в Бангалоре ...
Biocon ka Game Plan badal gaya? | Markets by Zerodha Hindi
Biocon ka Game Plan badal gaya? | Markets by Zerodha Hindi
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Biocon: U.S., European Markets Aided Growth In Q2
Biocon: U.S., European Markets Aided Growth In Q2
Biocon Biologics' CEO & MD Shreehas Tambe On Strong Q3, Future Demand | Partnership With Sandoz AG
Biocon Biologics' CEO & MD Shreehas Tambe On Strong Q3, Future Demand | Partnership With Sandoz AG
PwC Presents BT MindRush Pods: Biocon- Shaping The Future Of Biotechnology
PwC Presents BT MindRush Pods: Biocon- Shaping The Future Of Biotechnology
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Dr. Abhijit Barve, President, Research & Development, Biocon
Dr. Abhijit Barve, President, Research & Development, Biocon
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Dr. Shaw on future plans for Biocon:(Interview with ET Now).mpg
Dr. Shaw on future plans for Biocon:(Interview with ET Now).mpg
Biocon Eyes Equity Investments for Debt Reduction Says Kiran Mazumdar-Shaw | Exclusive | CNBC TV18
Biocon Eyes Equity Investments for Debt Reduction Says Kiran Mazumdar-Shaw | Exclusive | CNBC TV18
Biocon Signs Agreement With PiSA For Development Of rh-Insulin
Biocon Signs Agreement With PiSA For Development Of rh-Insulin
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
SCU MKTG3000 - Final Presentation Biocon
SCU MKTG3000 - Final Presentation Biocon
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY